Cargando…

Lymph Node and Bone Marrow Micrometastases Define the Prognosis of Patients with pN0 Esophageal Cancer

Background: Pathological routine lymph node staging is postulated to be the main oncological prognosticator in esophageal cancer (EC). However, micrometastases in lymph nodes (LNMM) and bone marrow (BNMM) are discussed as the key events in tumor recurrence. We assessed the prognostic significance of...

Descripción completa

Detalles Bibliográficos
Autores principales: Karstens, Karl-F., Ghadban, Tarik, Effenberger, Katharina, Sauter, Guido, Pantel, Klaus, Izbicki, Jakob R., Vashist, Yogesh, König, Alexandra, Reeh, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139797/
https://www.ncbi.nlm.nih.gov/pubmed/32143307
http://dx.doi.org/10.3390/cancers12030588
_version_ 1783518849276051456
author Karstens, Karl-F.
Ghadban, Tarik
Effenberger, Katharina
Sauter, Guido
Pantel, Klaus
Izbicki, Jakob R.
Vashist, Yogesh
König, Alexandra
Reeh, Matthias
author_facet Karstens, Karl-F.
Ghadban, Tarik
Effenberger, Katharina
Sauter, Guido
Pantel, Klaus
Izbicki, Jakob R.
Vashist, Yogesh
König, Alexandra
Reeh, Matthias
author_sort Karstens, Karl-F.
collection PubMed
description Background: Pathological routine lymph node staging is postulated to be the main oncological prognosticator in esophageal cancer (EC). However, micrometastases in lymph nodes (LNMM) and bone marrow (BNMM) are discussed as the key events in tumor recurrence. We assessed the prognostic significance of the LNMM/BNMM status in initially pN0 staged patients with curative esophagectomy. Methods: From 110 patients bone marrow aspirates and lymph node tissues were analyzed. For LNMM detection immunohistochemistry was performed using the anticytokeratin antibody AE1/AE3. To detect micrometastases in the bone marrow a staining with the pan-keratin antibody A45-B/B3 was done. Results were correlated with clinicopathologic parameters as well as recurrence and death during follow-up time. Results: Thirty-eight (34.5%) patients showed LNMM, whereas in 54 (49.1%) patients BNMM could be detected. LNMM and BNMM positive patients showed a correlation to an increased pT category (p = 0.017). Univariate and multivariate analyses revealed that the LNMM/BNMM status and especially LNMM skipping the anatomical lymph node chain were significant independent predictors of overall survival and recurrence-free survival. Conclusions: This study indicates that routine pathological staging of EC is insufficient. Micrometastases in lymph nodes and the bone marrow seem to be the main reason for tumor recurrence and they are a strong prognosticator following curative treatment of pN0 EC.
format Online
Article
Text
id pubmed-7139797
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71397972020-04-10 Lymph Node and Bone Marrow Micrometastases Define the Prognosis of Patients with pN0 Esophageal Cancer Karstens, Karl-F. Ghadban, Tarik Effenberger, Katharina Sauter, Guido Pantel, Klaus Izbicki, Jakob R. Vashist, Yogesh König, Alexandra Reeh, Matthias Cancers (Basel) Article Background: Pathological routine lymph node staging is postulated to be the main oncological prognosticator in esophageal cancer (EC). However, micrometastases in lymph nodes (LNMM) and bone marrow (BNMM) are discussed as the key events in tumor recurrence. We assessed the prognostic significance of the LNMM/BNMM status in initially pN0 staged patients with curative esophagectomy. Methods: From 110 patients bone marrow aspirates and lymph node tissues were analyzed. For LNMM detection immunohistochemistry was performed using the anticytokeratin antibody AE1/AE3. To detect micrometastases in the bone marrow a staining with the pan-keratin antibody A45-B/B3 was done. Results were correlated with clinicopathologic parameters as well as recurrence and death during follow-up time. Results: Thirty-eight (34.5%) patients showed LNMM, whereas in 54 (49.1%) patients BNMM could be detected. LNMM and BNMM positive patients showed a correlation to an increased pT category (p = 0.017). Univariate and multivariate analyses revealed that the LNMM/BNMM status and especially LNMM skipping the anatomical lymph node chain were significant independent predictors of overall survival and recurrence-free survival. Conclusions: This study indicates that routine pathological staging of EC is insufficient. Micrometastases in lymph nodes and the bone marrow seem to be the main reason for tumor recurrence and they are a strong prognosticator following curative treatment of pN0 EC. MDPI 2020-03-04 /pmc/articles/PMC7139797/ /pubmed/32143307 http://dx.doi.org/10.3390/cancers12030588 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Karstens, Karl-F.
Ghadban, Tarik
Effenberger, Katharina
Sauter, Guido
Pantel, Klaus
Izbicki, Jakob R.
Vashist, Yogesh
König, Alexandra
Reeh, Matthias
Lymph Node and Bone Marrow Micrometastases Define the Prognosis of Patients with pN0 Esophageal Cancer
title Lymph Node and Bone Marrow Micrometastases Define the Prognosis of Patients with pN0 Esophageal Cancer
title_full Lymph Node and Bone Marrow Micrometastases Define the Prognosis of Patients with pN0 Esophageal Cancer
title_fullStr Lymph Node and Bone Marrow Micrometastases Define the Prognosis of Patients with pN0 Esophageal Cancer
title_full_unstemmed Lymph Node and Bone Marrow Micrometastases Define the Prognosis of Patients with pN0 Esophageal Cancer
title_short Lymph Node and Bone Marrow Micrometastases Define the Prognosis of Patients with pN0 Esophageal Cancer
title_sort lymph node and bone marrow micrometastases define the prognosis of patients with pn0 esophageal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139797/
https://www.ncbi.nlm.nih.gov/pubmed/32143307
http://dx.doi.org/10.3390/cancers12030588
work_keys_str_mv AT karstenskarlf lymphnodeandbonemarrowmicrometastasesdefinetheprognosisofpatientswithpn0esophagealcancer
AT ghadbantarik lymphnodeandbonemarrowmicrometastasesdefinetheprognosisofpatientswithpn0esophagealcancer
AT effenbergerkatharina lymphnodeandbonemarrowmicrometastasesdefinetheprognosisofpatientswithpn0esophagealcancer
AT sauterguido lymphnodeandbonemarrowmicrometastasesdefinetheprognosisofpatientswithpn0esophagealcancer
AT pantelklaus lymphnodeandbonemarrowmicrometastasesdefinetheprognosisofpatientswithpn0esophagealcancer
AT izbickijakobr lymphnodeandbonemarrowmicrometastasesdefinetheprognosisofpatientswithpn0esophagealcancer
AT vashistyogesh lymphnodeandbonemarrowmicrometastasesdefinetheprognosisofpatientswithpn0esophagealcancer
AT konigalexandra lymphnodeandbonemarrowmicrometastasesdefinetheprognosisofpatientswithpn0esophagealcancer
AT reehmatthias lymphnodeandbonemarrowmicrometastasesdefinetheprognosisofpatientswithpn0esophagealcancer